Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative

symbol logo$JAZZ Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$3.88 down -147.72% YoY • Reported revenue of $1.24B up 10.38% YoY • Jazz Pharmaceuticals expects total revenues in 2026 to increase compared to 2025; cost of product sales to be in line, SG&A to decrease, and R&D expenses to increase compared to 2025.

Price since post

Full Details

Advertisement|Remove ads.